556 results on '"Colomer R"'
Search Results
2. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
3. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
4. Ring faulting and piston collapse in the mantle sustained the largest submarine eruption ever documented
5. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
6. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
7. Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
8. Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer
9. Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
10. Advanced breast cancer clinical nursing curriculum: review and recommendations
11. EP08.01-040 Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer
12. Evolución y resultados del tratamiento neoadyuvante en cáncer de mama durante un periodo de 10 años
13. Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
14. ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2+ BREAST CANCER IN SPAIN: A COST OFFSETS STUDY: C070
15. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
16. 1287P Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy
17. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey
18. Epigenetic regulation of gfi1 in endocrine-related cancers : A role regulating tumor growth
19. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
20. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
21. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
22. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb®) in human breast carcinoma cells
23. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
24. Creatine transporter deficiency in two adult patients with static encephalopathy
25. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial
26. 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
27. 46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
28. Seismicity in far western Nepal reveals flats and ramps along the Main Himalayan Thrust
29. PCN79 IMPACT of Adjuvant Trastuzumab Emtansine (T-DM1) on the Incidence of HER2-Positive Metastatic Breast Cancer and Its Associated Savings for the Spanish National Healthcare System
30. PCN110 Cost-Utility Analysis of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients with HER2+ EARLY Breast Cancer with Residual Invasive Disease after Neoadjuvant Therapy in Spain
31. PCN78 Costs of Recurrence in Patients with HER2+ Breast Cancer in Spain
32. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial
33. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
34. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer
35. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
36. Spain: Lexicography in Iberian Languages
37. Real-world treatment in patients with HER2+ metastatic breast cancer
38. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification
39. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells
40. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement
41. Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters
42. It Is Not Time to Stop Progesterone Receptor Testing in Breast Cancer
43. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
44. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells
45. Validation of the 2001 St Gallen Risk Categories for Node-Negative Breast Cancer Using a Database From the Spanish Breast Cancer Research Group (GEICAM)
46. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors
47. Current controversies in the management of early breast cancer
48. PCN117 COST-UTILITY ANALYSIS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY VERSUS TRASTUZUMAB AND CHEMOTHERAPY FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2+ EARLY BREAST CANCER IN SPAIN
49. Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
50. Lateral variations of the midcrustal seismicity in western Nepal: Seismotectonic implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.